Skip to main content
SpringerLink
Log in

Terapia medica della Sindrome di Cushing: aggiornamenti su Osilodrostat

  • FARMACI INNOVATIVI IN ENDOCRINOLOGIA
  • Published:
L'Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Bibliografia

  1. Feelders RA, Newell-Price J, Pivonello R, Nieman LK, Hofland LJ, Lacroix A (2019) Advances in the medical treatment of Cushing’s syndrome. Lancet Diabetes Endocrinol 7(4):300–312

    Article  PubMed  Google Scholar 

  2. Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, Barba L et al. (2020) Medical treatment of Cushing’s disease: an overview of the current and recent clinical trials. Front Endocrinol 11:648. https://doi.org/10.3389/fendo.2020.00648

    Article  Google Scholar 

  3. Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M et al. (2014) LCI699, a potent 11-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99(4):1375–1383. https://doi.org/10.1210/jc.2013-2117

    Article  CAS  PubMed  Google Scholar 

  4. Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T, Hilliard A et al. (2016) Osilodrostat, a potent oral 11\(\beta \)-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease. Pituitary 19:138–148. https://doi.org/10.1007/S11102-015-0692-Z

    Article  CAS  PubMed  Google Scholar 

  5. Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ et al. (2020) Efficacy and safety of osilodrostat in patients with Cushing’s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8:748–761. https://doi.org/10.1016/S2213-8587(20)30240-0

    Article  CAS  PubMed  Google Scholar 

  6. Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, Witek P, Belaya Z, Yu Y, Liao Z et al. (2022) Randomized trial of Osilodrostat for the treatment of Cushing disease. J Clin Endocrinol Metab 107:2882–2895. https://doi.org/10.1210/clinem/dgac178

    Article  Google Scholar 

  7. Ferraù F, Cannavò S (2020) Osilodrostat (LCI699) per la cura della sindrome di Cushing. Endocrinologo 21:305–306. https://doi.org/10.1007/s40619-020-00750-y

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Malattie Endocrine e Metaboliche, IRCCS Istituto Auxologico Italiano, Milano, Italia

    Valentina Morelli

  2. Dipartimento di Biotecnologie Mediche e Medicina Traslazionale, Università deli Studi di Milano, Milano, Italia

    Vittoria Favero

Authors
  1. Valentina Morelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vittoria Favero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Valentina Morelli.

Ethics declarations

Conflitto di interesse

Le Autrici dichiarano di non avere conflitti di interesse.

Consenso informato

Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.

Studi sugli animali

Le Autrici di questo articolo non hanno eseguito studi sugli animali.

Additional information

Proposto da C. Simeoli.

Nota della casa editrice

Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morelli, V., Favero, V. Terapia medica della Sindrome di Cushing: aggiornamenti su Osilodrostat. L'Endocrinologo 24, 87–90 (2023). https://doi.org/10.1007/s40619-023-01212-x

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40619-023-01212-x

Search

Navigation